Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Donaghue Medical Research Foundation | OTHER |
Not provided
Not provided
Not provided
Not provided
The objective of this study is to evaluate the impact of the value-based formulary on patient out-of-pocket spending and health plan spending as well as the impact of the value-based formulary on medication use, emergency department visits, hospitalizations, and outpatient office visits.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Value-based Formulary Beneficiaries | enrolled in the value-based formulary |
| |
| Standard Formulary Beneficiaries | enrolled in a standard (i.e., non-value-based formulary) |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Value-based Formulary | Other | Prescription drug formulary tiers informed by estimated value |
|
| Measure | Description | Time Frame |
|---|---|---|
| Total spending for prescription drugs | Impact of value-based formulary on patient out-of-pocket plus health plan spending on prescription drugs per member per month | From 24 months before insurance transition until up to 36 months after transition |
| Measure | Description | Time Frame |
|---|---|---|
| Patient out-of-pocket spending for prescription drugs | Impact of value-based formulary on patient out-of-pocket spending for prescription drugs per member per month | From 24 months before insurance transition until up to 36 months after transition |
| Health plan spending for prescription drugs |
Not provided
Inclusion Criteria:
Individuals:
aged 0-64
Continuously enrolled in an employer-sponsored health plan for at least 12 months (with one-month allowable gap) prior to the index date
Employer groups:
Exclusion Criteria:
- Individuals with:
Not provided
Not provided
All individuals who satisfy the eligibility criteria are included.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Kai Yeung, PharmD, PhD | Kaiser Permanente | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Kaiser Permanente | Seattle | Washington | 98101 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 37889867 | Derived | Yeung K, Cruz M, Tsiao E, Watkins JB, Sullivan SD. Drug use and spending under a formulary informed by cost-effectiveness. J Manag Care Spec Pharm. 2023 Nov;29(11):1175-1183. doi: 10.18553/jmcp.2023.29.11.1175. |
Not provided
Not provided
Individual participant data will not be made available per data use agreement.
Not provided
Not provided
Not provided
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| SAP | No | Yes | No | Statistical Analysis Plan | May 14, 2021 | May 14, 2021 | SAP_000.pdf |
Not provided
Not provided
Not provided
Not provided
Impact of value-based formulary on health plan spending for prescription drugs per member per month |
| From 24 months before insurance transition until up to 36 months after transition |
| Total healthcare spending | Impact of value-based formulary on total healthcare spending per member per month | From 24 months before insurance transition until up to 36 months after transition |
| Number of emergency department visits | Impact of value-based formulary on number of emergency department visits per member per month | From 24 months before insurance transition until up to 36 months after transition |
| Number of days in hospital | Impact of value-based formulary on number of days in hospital per member per month | From 24 months before insurance transition until up to 36 months after transition |
| Number of outpatient office visits | Impact of value-based formulary on number of outpatient office visits per member per month | From 24 months before insurance transition until up to 36 months after transition |
| Days supply of medication | Impact of value-based formulary on days supply of medication per member per month | From 24 months before insurance transition until up to 36 months after transition |